Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.

Philippon M, Morange I, Barrie M, Barlier A, Taieb D, Dufour H, Conte-Devolx B, Brue T, Castinetti F.

Ann Endocrinol (Paris). 2012 Jun;73(3):225-9. doi: 10.1016/j.ando.2012.03.001. Epub 2012 Apr 20.

PMID:
22520146
2.

A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.

Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, Ishida Y, Takano K, Okinaga H, Matsuno A.

Neurosurgery. 2011 Jun;68(6):E1761-7; discussion E1767. doi: 10.1227/NEU.0b013e318217161a.

PMID:
21389894
3.

Long-term response of pituitary carcinoma to temozolomide. Report of two cases.

Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE.

J Neurosurg. 2006 Oct;105(4):621-6.

PMID:
17044568
4.

Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report.

Guastamacchia E, Triggiani V, Tafaro E, De Tommasi A, De Tommasi C, Luzzi S, Sabbà C, Resta F, Terreni MR, Losa M.

Minerva Endocrinol. 2007 Sep;32(3):231-6.

PMID:
17912159
5.

SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.

Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, Thomé C.

Exp Clin Endocrinol Diabetes. 2010 Nov;118(10):760-3. doi: 10.1055/s-0030-1253419. Epub 2010 May 21.

PMID:
20496311
6.

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T.

J Clin Endocrinol Metab. 2010 Oct;95(10):4592-9. doi: 10.1210/jc.2010-0644. Epub 2010 Jul 21.

PMID:
20660056
7.

Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.

Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM.

Pituitary. 2007;10(1):81-6.

PMID:
17285366
8.

The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma.

Vieira Neto L, Chimelli L, Pereira PJ, Gasparetto EL, Bines J, Wildemberg LE, Gadelha MR.

Endocr Pract. 2013 Nov-Dec;19(6):e145-9. doi: 10.4158/EP12400.CR.

PMID:
23807517
9.

Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.

Felker J, Patterson B, Wrubel D, Janss A.

J Pediatr Endocrinol Metab. 2016 Dec 1;29(12):1413-1415. doi: 10.1515/jpem-2016-0159.

PMID:
27815961
10.

[Pituitary melanocytoma mimicking an adenoma].

Coulibaly B, Bouvier C, Paula AM, Fernandez C, Dufour H, Figarella-Branger D.

Ann Pathol. 2011 Feb;31(1):50-2. doi: 10.1016/j.annpat.2010.09.007. Epub 2011 Jan 26. French.

PMID:
21349390
11.

Temozolomide in aggressive pituitary adenomas and carcinomas.

Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, Horvath E, Kovacs K.

Clinics (Sao Paulo). 2012;67 Suppl 1:119-23. Review.

12.

Multiple endocrine neoplasia type 1.

Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Gozzini A, Luzi E, Brandi ML.

Orphanet J Rare Dis. 2006 Oct 2;1:38. Review.

13.

Prolactin secreting pituitary carcinoma.

Petterson T, MacFarlane IA, MacKenzie JM, Shaw MD.

J Neurol Neurosurg Psychiatry. 1992 Dec;55(12):1205-6.

14.

Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.

Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G.

N Engl J Med. 2003 Nov 20;349(21):2023-33.

15.

Temozolomide: a novel treatment for pituitary carcinoma.

Lim S, Shahinian H, Maya MM, Yong W, Heaney AP.

Lancet Oncol. 2006 Jun;7(6):518-20. No abstract available.

PMID:
16750503
17.

Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.

Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE.

Hum Pathol. 2007 Jan;38(1):185-9. Epub 2006 Oct 23. Erratum in: Hum Pathol. 2007 Mar;38(3):526.

PMID:
17056093
18.

Chronic anemia as first clinical manifestation of a prolactin-secreting pituitary macroadenoma in a male patient.

Iglesias P, Díez JJ.

Am J Med. 2011 Jun;124(6):e3-4. doi: 10.1016/j.amjmed.2010.12.023. No abstract available.

PMID:
21605718
19.

Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.

Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M, Bonnet F, Bourcigaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assié G, Raverot G.

Eur J Endocrinol. 2017 Jun;176(6):769-777. doi: 10.1530/EJE-16-0979.

PMID:
28432119
20.

Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management.

Zemmoura I, Wierinckx A, Vasiljevic A, Jan M, Trouillas J, François P.

Pituitary. 2013 Dec;16(4):515-22. doi: 10.1007/s11102-012-0448-y.

PMID:
23184261

Supplemental Content

Support Center